Solodyn is owned by Bausch.
Solodyn contains Minocycline Hydrochloride.
Solodyn has a total of 8 drug patents out of which 0 drug patents have expired.
Solodyn was authorised for market use on 08 May, 2006.
Solodyn is available in tablet, extended release;oral dosage forms.
Solodyn can be used as treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris, treatment of acne.
The generics of Solodyn are possible to be released after 17 November, 2031.
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8722650 | BAUSCH | Extended-release minocycline dosage forms |
Jun, 2025
(2 years from now) | |
US8252776 | BAUSCH | Minocycline oral dosage forms for the treatment of acne |
Jun, 2025
(2 years from now) | |
US8268804 | BAUSCH | Minocycline oral dosage forms for the treatment of acne |
Jun, 2025
(2 years from now) | |
US7790705 | BAUSCH | Minocycline oral dosage forms for the treatment of acne |
Jun, 2025
(2 years from now) | |
US7919483 | BAUSCH | Method for the treatment of acne |
Mar, 2027
(4 years from now) | |
US7544373 | BAUSCH | Minocycline oral dosage forms for the treatment of acne |
Apr, 2027
(4 years from now) | |
US7541347 | BAUSCH | Minocycline oral dosage forms for the treatment of acne |
Apr, 2027
(4 years from now) | |
US9192615 | BAUSCH | Method for the treatment of acne and certain dosage forms thereof |
Nov, 2031
(8 years from now) |
Drugs and Companies using MINOCYCLINE HYDROCHLORIDE ingredient
Market Authorisation Date: 08 May, 2006
Treatment: Treatment of acne; Treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris
Dosage: TABLET, EXTENDED RELEASE;ORAL
23
United States
2
Japan
1
South Africa
1
Australia
1
Norway
1
New Zealand
1
Canada
1
China
1
European Union
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic